12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

Verastem, S*BIO, Eisai, Pfizer deal

Last week, cancer stem cell company Verastem provided a pipeline update and announced three deals. Pfizer granted Verastem exclusive, worldwide rights to develop and commercialize VS-6063 (formerly PF-04554878). The inhibitor of focal adhesion kinase (FAK) completed a Phase I trial in advanced solid tumors. Pfizer will receive $1.5 million up front, as well as 192,012 Verastem shares valued at $2 million based on the Verastem's close of $10.19 on July 11, the day the deal was announced. Pfizer is eligible...

Read the full 408 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >